Key clinical point:
Major finding: After 24 weeks, the endoscopic nasal polyp score averaged a clinically meaningful 2.06 points lower on dupilumab, compared with placebo.
Study details: SINUS-24, a multicenter randomized trial with 276 patients.
Disclosures: SINUS-24 was funded by Regeneron and Sanofi, the companies that market dupilumab (Dupixent). Dr. Han has been an adviser to Regeneron and Sanofi.
Han JK et al. AAAAI,.